Phase 3
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Phase 3 · randomised · 700 people · 251 sites in 26 countries · Recruiting now
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Phase 3 · randomised · 1,000 people · 239 sites in 22 countries · Recruiting now
-
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Phase 3 · randomised · 700 people · 297 sites in 22 countries · Recruiting now
-
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · randomised · 600 people · 243 sites in 15 countries · Recruiting now
-
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 3 · randomised · 990 people · 286 sites in 25 countries · Recruiting now
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 3 · randomised · 1,912 people · 1,085 sites in 3 countries · Recruiting now
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer
Phase 3 · randomised · 477 people · 245 sites in 29 countries · Recruiting now